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Background: In the setting of stable coronary artery disease (CAD), it is not known if the pleiotropic effects of
cholesterol reduction differ between combined ezetimibe/simvastatin and high-dose simvastatin alone.
Objective:We sought to compare the anti-inﬂammatory and antiplatelet effects of ezetimibe 10 mg/simvastatin
20 mg (E10/S20) with simvastatin 80 mg (S80).
Methods and results: CAD patients (n=83, 63±9 years, 57% men) receiving S20, were randomly allocated to
receive E10/S20 or S80, for 6 weeks. Lipids, inﬂammatory markers (C-reactive protein, interleukin-6, monocyte
chemoattractant protein-1, soluble CD40 ligand and oxidized LDL), and platelet aggregation (platelet function
analyzer [PFA]-100) changes were determined. Baseline lipids, inﬂammatorymarkers and PFA-100were similar
between groups. After treatment, E10/S20 and S80 patients presented, respectively: (1) similar reduction in
LDL-C (29±13% vs. 28±30%, p=0.46), apo-B (18±17% vs. 22±15%, p=0.22) and oxidized LDL (15±33% vs.
18±47%, p=0.30); (2) no changes in inﬂammatory markers; and, (3) a higher increase of the PFA-100 with
E10/S20 than with S80 (27±43% vs. 8±33%, p=0.02).
Conclusions: These data suggest that among stable CAD patients treated with S20, (1) both E10/S20 and S80
were equally effective in further reducing LDL-C; (2) neither treatment had any further signiﬁcant
anti-inﬂammatory effects; and (3) E10/S20 was more effective than S80 in inhibiting platelet aggregation.
Thus, despite similar lipid lowering and doses 4× less of simvastatin, E10/S20 induced a greater platelet
inhibitory effect than S80.
© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Among patients with coronary artery disease (CAD), a robust
evidence base supports the beneﬁcial effects of statin therapy on
mortality and other adverse cardiovascular outcomes [1]. Previously,
two large trials [2,3], have demonstrated that compared to standard
dose statin therapy or placebo, high statin doses reduced low-densityMUSP), Av. Enéas de C. Aguiar,
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e Elsevier OA license.cholesterol lipoprotein (LDL-C) to extremely low levels and decreased
coronary events, even in patients without elevated levels of LDL-C.
Subsequently, recent guidelines have suggested an LDL-C treatment
goal of b70 mg/dL in patients with CAD [4]. Achieving such low LDL-C
levels frequently demands an intensive LDL-C reduction, often above
50%. Ezetimibe, an intestinal cholesterol absorption inhibitor, can be
used as an additional therapy if statin monotherapy fails to reduce
LDL-C below the treatment goal [5].
Furthermore, anti-inﬂammatory and antithrombotic pleiotropic
effects of statins might explain, at least in part, the large beneﬁts
demonstrated in randomized trials [6,7]. For example, in hypercho-
lesterolemic patients treatedwith statins, a decrease in inﬂammation-
associated markers such as the C-reactive protein (CRP) has been
described [8], although it is debated whether this effect is clearly
independent of LDL-C [9].
Moreover, although inhibition of platelets by statin therapy is a
well established effect [10], it has not yet been clariﬁed whether
platelet inhibition by statin therapy depends on the reduction of LDL-
Table 1
Baseline characteristics of the patients, according to treatment group.
Characteristic Simvastatin 80 mg
(S80) (n=38)
Ezetimibe 10 mg/simvastatin
20 mg (E10/S20) (n=40)
Men (%) 21 (55) 27 (68)
Median age, in years 61.7±10 64.5±9
Body mass index, in kg/m2 27.8±2.7 28.6±3.7
Coronary risk factor
Diabetes mellitus (%) 20 (52) 16 (40)
Hypertension (%) 26 (68) 36 (90)
Habitual smoker (%) 8/35 (23) 5/39 (13)
Previous myocardial
infarction (%)
29 (76) 24 (60)
Previous percutaneous
coronary intervention (%)
16 (42) 16 (40)
Previous coronary artery
bypass grafting (%)
13 (34) 16 (40)
Previous stroke (%) 3 (8) 3 (8)
Concomitant medication (%)
ACE inhibitor or AT-1
receptor blocker (%)
32 (84) 35 (88)
ASA, 100 mg/day (%) 35 (92) 37 (93)
Clopidogrel 75 mg/day (%) 1 (2.6) 1 (2.5)
Data are expressed as mean±SD or n (%). ASA, acetyl salicylic acid; ACE, angiotensin
converting enzyme inhibitor; AT, angiotensin.
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disaggregating effects [11].
Two alternative pharmacologic strategies are equally effective in
reducing LDL-C: high-dose statin alone and combined treatment with
ezetimibe plus moderate-dose statin [12]. It is not known whether
these two strategies have different cholesterol-independent pleiotro-
pic effects on inﬂammation and platelets. We therefore compared the
anti-inﬂammatory and antiplatelet effects of two intensive pharma-
cologic strategies designed to reduce cholesterol to a similar extent:
ezetimibe 10 mg/simvastatin 20 mg (E10/S20) versus simvastatin
80 mg (S80).
2. Methods
2.1. Study design
From July 2006 to January 2009, we randomized 83 patients with stable CAD in a
single tertiary specialized cardiology hospital. These patients had LDL-C N70 mg/dL
despite ongoing treatment with 20 mg/day of simvastatin for more than four weeks. In
addition, the patients met the following inclusion criteria: angiographically documen-
ted CAD, stable angina, and age between 18 and 80 years. Exclusion criteria were a
history of myocardial infarction or revascularization within the last 3 months,
moderate/severe left ventricular systolic dysfunction, warfarin treatment, malignancy,
inﬂammatory diseases, severe renal insufﬁciency (creatinine N1.5 mg/dL), active liver
disease or known liver cirrhosis and unclariﬁed transaminase increase (N3 fold of
normal).
Patients were randomly assigned in a double blind fashion and 1:1 ratio, to receive
either E10/S20 or S80 for six weeks. The experimental regimen was initiated without a
washout period of simvastatin. Fasting venous blood samples, drawn immediately after
randomization and at the conclusions of the six week study period, were used for
evaluation of the following biomarkers: CRP, interleukin (IL)-6, monocyte chemoat-
tractant protein (MCP)-1, oxidized LDL-C (oxLDL) and soluble CD40 ligand (sCD40L).
Platelet aggregation and lipid levels (LDL-C, high density lipoprotein cholesterol [HDL-
C], triglycerides [TG] and apolipoproteins [apo] A and B) were also compared between
the two strategies.
An informedconsentwas obtained fromeachpatient and the studyprotocol conforms
to the ethical guidelines of the 1975 Declaration of Helsinki as reﬂected in an a priori
approval by the institution's human research committee.
2.2. Platelet aggregation by PFA-100 assay
Samples were collected in 3.8% sodium citrate (buffered, pH 5.5, Vacutainer, Becton
Dickinson, UK) for platelet function tests. Platelet function assays were processed
within 2 h of blood collection. The PFA-100 point-of-care assay (Dade-Behring, USA)
utilizes a cartridge that contains a capillary, a sample reservoir, a collagen/epinephrine-
coated membrane, and an aperture that exposes platelets to high shear conditions.
When platelets in whole blood come in contact with epinephrine and collagen, they
become activated and aggregate at the aperture, and thus gradually reduce and ﬁnally
arrest blood ﬂow. The PFA-100 records the closure time (CT), which means the time in
seconds (s) from the start of the test until the platelet plug occludes the aperture. We
deﬁned the upper limit of 150 s (collagen/epinephrine cartridge, citrate 3.8%) for a
normal PFA-100 CT, according to previous investigation and label recommendation
[13].
2.3. CRP, IL-6, MCP-1, sCD40L and oxLDL
Serum was separated by centrifugation from the blood samples. For high-sensitivity
CRPmeasurement, whole venous blood was collected in tubes without anticoagulant and
centrifuged at room temperature. Serum CRP was assessed with a high-sensitivity, latex
microparticle-enhanced immunoturbidimetric assay (BN II analyzer, Dade Behring, USA).
The minimum detectable concentration of CRP was 0.2 mg/L. For the other markers,
serum samples were stored at−70 °C and were determined simultaneously by ELISA in
order to avoid variation of assay conditions. Commercial ELISA assays detecting MCP-1
(R&D Systems, UK), IL-6 (Siemens, USA), sCD40L (R&D Systems, USA) and oxLDL
(Mercodia, USA) were applied. Detection limits and intra-assay variability of ELISA assays
were respectively, as follows: MCP-1, 5 pg/mL and 4.7%; IL-6, 2 pg/mL and 6%, sCD-40 L
15.6 pg/mL (intra-assay variability not available); oxLDL 0.3 U/I and 6.1%.
2.4. End points
The primary endpoint was CRP and the secondary end points were PFA-100, IL-6,
MCP-1, sCD40L, oxLDL and lipid proﬁle measures at 6 weeks after randomization.
2.5. Statistical analysis
The sample size was determined as 72 patients. This would enable the study to
have a power of 80%, with a 2-tailed type I error of 0.05, to detect a difference of 2 mg/L
between the geometric means of CRP of the study groups, assuming a standarddeviation of 3 mg/L [9,14] Continuous data were presented as means±SD, or median
(25th and 75th percentiles) when the distribution was non-normal. For qualitative
variables, we presented counts and relative frequencies. Paired t-test was used for
before–after intra-group comparisons when the distribution was normal, otherwise we
used the Wilcoxon signed-rank test. For comparison between treatment groups we
used multiple regression with adjustment only for the baseline values of the outcome
variable (ANCOVA) or Wilcoxon rank-sum test when the variable was not normally
distributed. Correlations between continuous variables were analyzed with Pearson's r
statistics. Differences between the results with a p value of less than 0.05 were
considered to be statistically signiﬁcant. We did not adjust P values for multiple
comparisons. All analyses were performed using STATA/SE 9.2 (Stata Corp LP, USA).
3. Results
Premature discontinuation of the study drugs occurred in ﬁve
patients (2 in the E10/S20 group and 3 in the S80 group). Therefore,
78 patients (62% men, mean age 63±9 years) remained for statistical
analysis (38 in the S80 group and 41 in the E10/S20 group). Baseline
characteristics, as well as lipid and inﬂammatory proﬁles were similar
between the two treatment groups (Tables 1, 2 and 3). Notably, the
initial cholesterol and inﬂammatory levels were relatively low in the
whole population, due to the fact that all patients were previously on
20 mg of simvastatin for at least 4 weeks.
3.1. Change in serum lipid levels and biochemical variables
Total cholesterol, LDL-C and apo-B plasma concentrations were
signiﬁcantly reduced by treatments in both groups, while HDL-C and
apo-A plasma concentrations remained unchanged (Table 2). The TG
levels were reduced signiﬁcantly by E10/S20, but not by S80.
However, there were no signiﬁcant differences between the changes
in all lipid parameters among the two treatment groups, indicating a
comparable effect of the study medications on lipid levels (Table 2).
Liver and muscle parameters were unaffected.
3.2. Change in inﬂammatory markers and oxLDL
No signiﬁcant differences were observed at baseline comparing
the two groups. No signiﬁcant reductionwas notedwithin or between
groups for CRP or any of the other inﬂammatory markers (IL-6, sCD-
40L and MCP-1; Table 3 and Fig. 1). Oxidized LDL-C was equally
Table 2
Treatment effects on plasma lipid levels.
Simvastatin 80 mg
(S80) (n=38)
Ezetimibe 10/simvastatin
20 mg (E10/S20) (n=40)
p
Total cholesterol, mg/dL
Pre-treatment 170.5 (155–212) 175 (157–195) 0.74
Post-treatment 143 (117–160) 143 (127–157)
p: post vs. pre b0.01 b0.01
Median change (%) −20 (9–27) −20 (13–27) 0.76
LDL-C, mg/dL
Pre-treatment 101 (85–130) 99 (89–117) 0.83
Post-treatment 76 (61–90) 72 (62–80)
p: post vs. pre b0.01 b0.01
Mean change (%) −28±30 −29±13 0.46
HDL-C, mg/dL
Pre-treatment 45 (38–50) 42 (37–48) 0.87
Post-treatment 42 (38–48) 43 (38–49)
p: post vs. pre 0.16 0.38
Mean change (%) −1±14 2±11 0.45
TG, mg/dL
Pre-treatment 117 (85–150) 139 (108–168) 0.07
Post-treatment 104 (91–127) 112 (77–149)
p: post vs. pre 0.07 0.01
Mean change (%) −4±32 −14±31 0.67
Apo A, mg/dL
Pre-treatment 1.6 (1.4–1.7) 1.6 (1.4–1.7) 0.26
Post-treatment 1.58 (1.4–1.7) 1.5 (1.4–1.7)
p: post vs. pre 0.97 0.17
Mean change (%) 0.8±13 −2±12 0.34
Apo B, mg/dL
Pre-treatment 0.9 (0.7–1.0) 0.9 (0.8–1.0) 0.58
Post-treatment 0.7 (0.6–0.8) 0.7 (0.7–0.9)
p: post vs. pre b0.01 b0.01
Mean change (%) −22±15 −18±17 0.22
Data are expressed as mean±SD or median (interquartile range). HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride;
Apo, apolipoprotein.
Table 3
Change in inﬂammatory markers and platelet aggregation.
Simvastatin 80 mg
(S80) (n=38)
Ezetimibe 10/simvastatin
20 mg (E10/S20) (n=40)
p
hs-CRP, mg/L
Pre-treatment 2.3 (0.7–5.5) 1.7 (0.72–3.65) 0.27
Post-treatment 1.8 (0.5–4.1) 1.27 (0.8–3.7)
p: post vs. pre 0.1 0.5
Median change (%) −16 (−42 to 7) −11 (−37 to 26) 0.30
IL-6, pg/mL
Pre-treatment 2.9 (2.0–4.3) 2.1 (2.0–3.5) 0.18
Post-treatment 2.3 (2.0–4.2) 2.0 (2.0–4.3)
p: post vs. pre 0.55 0.23
Median change (%) 0 (−22 to 24) 0 (−14 to 0) 0.8
sCD-40 L, pg/mL
Pre-treatment 10.8 (8.9–15.5) 11.0 (9.5–15.1) 0.63
Post-treatment 10.8 (8.6–14.8) 11.2 (9.4–16.4)
p: post vs. pre 0.53 0.56
Mean change (%) 6±43 6±34 0.48
MCP-1, pg/mL
Pre-treatment 230 (190–170) 200 (175–295) 0,52
Post-treatment 240 (185–275) 235 (190–285)
p: post vs. pre 0.47 0.11
Mean change (%) 11±47 10±21 0.85
oxLDL, ui
Pre-treatment 75 (54–99) 67 (54–100) 0.93
Post-treatment 55 (37–76) 58 (38–83)
p: post vs. pre b0.01 b0.01
Mean change (%) −18±47 −15±33 0.65
PFA-100 CT, seconds
Pre-treatment 131 (94–204) 145 (103–191) 0.83
Post-treatment 145 (89–198) 171 (122–244)
p: post vs. pre 0.9 b0.01
Mean change (%) 8±34 27±43 0.02
Data are expressed as mean±SD or median (interquartile range). CRP, C-reactive
protein; IL, interleukin; MCP-1, monocyte chemotactic protein-1; oxLDL, oxidized LDL;
sCD40L, soluble CD40 ligand; PFA-100 CT, Platelet Function Analyzer closure time.
Fig. 1. Percentual changes of LDL-C and inﬂammatory markers between randomized
treatment groups. The ﬁgure shows similar effects of both treatments on LDL-C and
inﬂammatory markers. E10/S20, ezetimibe 10 mg/simvastatin 20 mg; S80, simvas-
tatin 80 mg; LDL-C, cholesterol LDL; CRP, C-reactive protein; MCP-1, monocyte
chemoattractant protein-1; oxLDL, oxidized LDL; sCD40L, soluble CD40 ligand. Error
bars indicate standard error. Asterisks indicate that the p value was b0.01 for the
difference post vs. pre-treatment intra-group. IL-6 was not changed in both groups
(data in Table 3).
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respectively). We found a modest correlation between oxLDL and
LDL-C reductions (r=0.27, p=0.02).3.3. Change in platelet aggregation
The baseline PFA-100 median closure time levels were similar and
in the normal range in both groups (145 s vs. 131 s for E10/S20 and
S80 respectively, p=0.83, Table 3), despite the fact that 95% of the
patients were previously receiving treatment with acetyl salicylic acid
(ASA). The PFA-100 CT increased signiﬁcantly with E10/S20 but not
with S80 mg (Fig. 2). The comparison between groups demonstrated
a higher increase of the PFA-100 CT with E10/S20 than with S80
(27±43% vs. 8±34%, p=0.02). Additionally, the changes in PFA-100
CT were not correlated to LDL-C reduction in both groups (r=0.01;
p=0.93), but modestly correlated to TG reduction (r=0.25;
p=0.04).Fig. 2. Platelet Function Analyzer-100 closure times (seconds) at baseline (pre-treatment)
and 6 weeks (post-treatment) in both groups. The ﬁgure shows a signiﬁcant increase of
the PFA-100 closure time with E10/S20 but not with S80. Data is presented as medians,
10th, 25th, 75th and 90th percentiles. E10/S20, ezetimibe 10 mg/simvastatin 20 mg; S80,
simvastatin 80 mg.
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Our study has three main ﬁndings. First, among stable CAD
patients previously treated with S20 and with an average LDL-C of
100 mg/dL, E10/S20 and S80 were equally effective in further
reducing LDL-C. Second, neither treatment had any further signiﬁcant
anti-inﬂammatory effect. Finally, E10/S20 was more effective than
S80 in inhibiting platelet function.
The study population included patients with CAD in a common
clinical situation, in that they were already taking moderate intensity
statin therapy (S20), but still above the optimal LDL-C therapeutic
goal according to recent guidelines [4]. The study was designed
speciﬁcally to evaluate pleiotropic effects, and as expected from prior
studies, E10/S20 and S80 had similar effects on lipids [12]. Therefore,
we hypothesized that any differences observed between groups in
other parameters would not be related to LDL-C decrease, but to
speciﬁc pharmacologic features.
4.1. Anti-inﬂammatory effects of E10/S20 and S80
In previous studies, differences on CRP reduction were described
between statins and the combination of ezetimibe/statin [12].
However, these studies did not compare CRP changes between
equivalent lipid lowering doses of these agents and therefore the
LDL-C was often differentially reduced between groups. Consequent-
ly, pleiotropic effects could not be appropriately evaluated, since any
difference in anti-inﬂammatory effect between therapies could be
related mainly to distinct LDL-C reductions. In fact, a recent clinical
trial that compared ezetimibe/simvastatin and simvastatin strategies
to achieve aggressive cholesterol goals (target LDL-C b70 mg/dL)
demonstrated equivalent CRP reduction between groups [15].
Recently, Azar et al. [16] demonstrated that ezetimibe compared to
placebo, on top of atorvastatin, strongly reduced oxLDL in patients
with CAD. Evidently, the ezetimibe group had a larger reduction in
LDL-C. Moreover, the change in oxLDL correlated signiﬁcantly with
the LDL-C decrease. On the other hand, to our knowledge, our study
was the ﬁrst one that demonstrated similar oxLDL reductions
between comparable lipid lowering doses of the combination
ezetimibe/simvastatin and simvastatin alone.
The fact that the inﬂammatory markers (CRP, IL-6, MCP-1 and
sCD40L) were not reduced by either treatment strategy might be
explained by the following reasons: (1) As described above, the initial
inﬂammatory levels were already low in our population. This may be
related to the fact that patients were receiving guideline-based
treatment (aspirin, angiotensin converting enzyme inhibitor, angio-
tensin type 1 receptor blocker and S20) before randomization and the
study did not include a washout period before randomization. (2) The
period of six weeks may not be long enough to detect some of the
anti-inﬂammatory effects of these treatments. (3) Some of the anti-
inﬂammatory effects of statins may be concentrated in moderate
doses. Blanco-Colio et al. [17], for example, demonstrated that
atorvastatin 10 mg reduced the levels of the intercellular adhesion
molecule-1. However, the increase of the drug to 80 mg did not
show any additional reduction. Similarly, in the Aggrastat to Zocor
(A to Z trial), minimal difference in MCP-1 was seen between patients
receiving S80 or S20 [18].
These data do not suggest differences in pleiotropic anti-
inﬂammatory effects between E10/S20 and S80. Moreover, the effect
of these strategies on oxLDL seems to be related mainly to cholesterol
reduction and not to any pleiotropic effect.
4.2. Antiplatelet effects of E10/S20 and S80
In our study, E10/S20 was more effective than S80 in inhibiting
platelet aggregation, despite similar LDL-C reductions between groups.
The treatment with E10/S20, differently from S80, signiﬁcantlyincreased the PFA-100 CT, an effect that could not be entirely explained
by cholesterol reduction. However, this ﬁnding should be interpreted
with caution since it was one of many comparisons in our study, which
may increase the chance of a spurious statistically signiﬁcant associa-
tion. Nevertheless, this study shows for the ﬁrst time that ezetimibe/
simvastatin, at therapeutic concentrations, can inhibit platelet function,
a potential beneﬁcial pleiotropic effect of this combination.
Despite the previous use of ASA (100 mg/day) in 95% of the
evaluated population, the median initial PFA-100 CT was in the nor-
mal range in 56% of the patients. Other studies have also reported high
residual platelet aggregation among patients receiving aspirin [19],
particularly in patients using low doses [20]. On the other hand, lipids
may increase platelet aggregation by several mechanisms [21]:
(1) LDL-C, HDL-C and apolipoproteins bind speciﬁc receptors on the
platelet membrane, promoting thromboxane synthesis, glycoprotein
IIbIIIa expression and calcium inﬂux [22]; (2) Modiﬁcation of native
LDL-C generates a platelet-activating particle [23]; and, (3) Triglycer-
ides may also be related to platelet function. Kunes et al. [24] demon-
strated that lowering TG by gemﬁbrozil increases platelet membrane
microviscosity and reduces cytosolic Ca2+ in rats. Subsequently,
Karepov et al. [25] demonstrated that hypertriglyceridemia reduces
platelet response to aspirin.
Concomitantly, several investigators have evaluated the effects of
statins and ezetimibe on platelet function. However, these studies
were small and performed different and poorly reproducible platelet
evaluation methodologies [11,19,26–29]. Moreover, it is not clear if
these effects were related to cholesterol reduction, pleiotropic effects
or both. In patients with hypercholesterolemia, statins decreased
thrombin and thromboxane levels [26]. Tirnaksiz et al. performed the
PFA-100 CT measurement in patients with CAD and demonstrated a
signiﬁcant reduction in aspirin resistance after treatment with
atorvastatin [27]. In contrast, other investigators did not ﬁnd any
antiplatelet effect evaluated by ﬂow cytometry and turbidimetric
aggregometry, after treatment with E10/S10 or S80, in diabetic
patients [28]. Hussein et al. [29] demonstrated that ezetimibe
decreases platelet aggregation, LDL-C peroxidation and platelet
cholesterol content. Interestingly, this antiplatelet effect was not
present when simvastatin was associated to ezetimibe. Recently,
Piorkowski et al. [11] evaluated 56 patients with CAD and demon-
strated a signiﬁcant reduction of P-selectin and platelet aggregation
by 40 mg of atorvastatin, but not with 10 mg of ezetimibe/10 mg of
atorvastatin, despite similar reduction on LDL-C. However, only 38
patients were submitted to optical aggregometry in this study and the
platelet effect was not different between groups.
In our study, we performed the PFA-100, a simple and automatic
point-of-care assay. Importantly, the PFA system is known to
demonstrate a sensitivity of 95% and a speciﬁcity of 89% for the
evaluation of platelet function status, compared with classical
aggregometry [30]. We demonstrated a higher increase of the PFA-
100 CT with E10/S20 than with S80 (27±43% vs. 8±34%, respec-
tively, p=0.02). This result could be partially explained by a
signiﬁcant decrease on TG levels achieved by E10/S20, but not by
S80. In fact, the increase in PFA-100 was modestly, but signiﬁcantly,
correlated to TG reduction (r=0.25; p=0.04). Alternatively, platelet
aggregation may be inﬂuenced by several lipid aspects, beyond LDL-C
levels, as the platelet cholesterol content, platelet membrane ﬂuidity,
LDL peroxidation and HDL-C afﬁnity to binding proteins on platelet
membrane [21]. Actually, studies on the effect of ezetimibe on these
parameters are lacking. Moreover, the antiplatelet effect of ezetimibe
is poorly understood and larger studies are needed to conﬁrm these
antithrombotic properties.
5. Study limitations
Theprevious use of S20 for at least 4 weeks and the absence of awash-
out period before randomization may have inﬂuenced the subsequent
404 A.E.P. Pesaro et al. / International Journal of Cardiology 158 (2012) 400–404inﬂammatory changes. The PFA-100 results should be interpreted
considering the fact that it was part of a multiple endpoint ﬁnding.
6. Conclusion
The present study provides evidence that among stable CAD
patients treated with S20 to an average LDL-C of 100 mg/dL, (1) both
E10/S20 and S80 are equally effective in further reducing LDL-C, (2)
neither treatment had any further signiﬁcant anti-inﬂammatory
effects, and (3) E10/S20 is more effective than S80 in inhibiting
platelet aggregation. Thus, despite similar lipid lowering and doses 4×
less of simvastatin, E10/S20 induced a greater platelet inhibitory effect
than S80, a ﬁnding that merits further investigation.
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